Rankings / Cardiovascular & Lipids
Ezetimibe
CV/Lipid · NPC1L1 inhibitor
Tier B+
What this is
Generic, inexpensive, exceptionally well-tolerated. Should be first-line add-on when statin monotherapy is insufficient. Often underused. IMPROVE-IT 2015 established CV benefit of ezetimibe-on-statin in post-ACS.
Mechanism
Inhibits Niemann-Pick C1-like 1 transporter at intestinal brush border; reduces dietary and biliary cholesterol absorption; ~15-20% LDL reduction as monotherapy; synergistic with statins
Dose & route
10 mg PO daily
Citations
- https://pubmed.ncbi.nlm.nih.gov/26039521/
- https://pubmed.ncbi.nlm.nih.gov/23470236/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5363762/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.